Alphamab Oncology (ALPHAMAB-B) has filed its Monthly Return for the period ended 30 June 2026, detailing marginal movements in share capital driven solely by treasury share repurchases.

Total authorised capital unchanged • Authorised share capital remained at 25.10 billion ordinary shares with a par value of USD0.000002, equivalent to USD50,200.

Issued-share base edged lower • Outstanding shares (ex-treasury) fell by 156,000 to 968.51 million, a 0.02% month-on-month reduction. • Total issued shares were unchanged at 974.38 million, while treasury stock increased by the same 156,000 shares to 5.88 million.

On-market repurchase activity • On 4 June 2026, the company repurchased 156,000 shares at HKD7.106 each, costing approximately HKD1.11 million. All repurchased shares were held as treasury stock. • No shares were cancelled during the month.

Equity incentive schemes: no dilution in June • Pre-IPO Share Option Plan I: 9.21 million options outstanding; 2.31 million shares reserved for potential future issuance. • Pre-IPO Share Option Plan II: 4.84 million options outstanding; 3.32 million shares available for issue. • Post-IPO Share Option Plan: 0.98 million options outstanding; 0.36 million shares available for issue; overall scheme mandate allows a further 95.41 million shares.

No new shares were issued, and no treasury shares were transferred to satisfy option or award exercises during the month.

Public float intact • The company affirmed compliance with the Hong Kong Exchange’s 25% minimum public float requirement as of 30 June 2026.

Financial impact • With no share issuances and a modest repurchase outlay, the equity structure remains stable while shareholder value benefits from the slight reduction in outstanding shares.

All figures are sourced directly from the Hong Kong Stock Exchange filing dated 7 July 2026.